Diagnostic Microbiology and Infectious DiseaseGenetic & Genomic MedicinePeer-reviewed journal article
Y380Q novel mutation in receptor-binding domain of SARS-CoV-2 spike protein together with C379W interfere in the neutralizing antibodies interaction
Ivaine Taís Sauthier SartoriD, Fernanda Hammes VarelaiD, Mariana Rost MeirelesiD, Luciane Beatriz KerniD, Thaís Raupp AzevedoiD, Gabriela Luchiari Tumioto GianniniiD, Mariana Soares da SilvaiD, Meriane DemolineriD, Juliana Schons GularteiD, Paula Rodrigues de AlmeidaiD, Juliane Deise FleckiD, Gabriela Oliveira ZavagliaiD, Ingrid Rodrigues FernandesiD, Caroline Nespolo de DavidiD, Amanda Paz SantosiD, Walquíria Aparecida Ferreira de AlmeidaiD, Victor Bertollo Gomes PôrtoiD, Marcelo Comerlato ScottaiD, Gustavo Fioravanti VieiraiD, Fernando Rosado SpilkiiD, Renato Tetelbom SteiniD, Márcia Polese-BonattoiD, COVIDa study group
Abstract
BackgroundThe emergence of SARS-CoV-2 variants is a current public health concern possibly impacting COVID-19 disease diagnosis, transmission patterns and vaccine effectiveness. ObjectivesTo describe the SARS-CoV-2 lineages circulating early pandemic among samples with S gene dropout and characterize a novel mutation in receptor-binding domain (RBD) of viral spike protein. Study designAdults and children older than 2 months with signs and symptoms of COVID-19 were prospectively enrolled from May to October 2020 in Porto Alegre, Brazil. All participants performed RT-PCR assays for diagnosing SARS-CoV-2, samples with S gene dropout and Ct < 30 (cycle threshold) were submitted to whole genome sequencing (WGS), and homology modeling and physicochemical properties analysis were performed. Results484/1,557 participants tested positive for SARS-CoV-2. The S gene dropout was detected in 7.4% (36/484) as early as May, and a peak was observed in early August. WGS was performed in 8 samples. The B.1.1.28, B.1.91 and B.1.1.33 lineages were circulating in early pandemic. The RBD novel mutation (Y380Q) was found in one sample occurring simultaneously with C379W and V395A, and the B.1.91 lineage in the spike protein. ConclusionMutations in the SARS-CoV-2 spike region were detected early in the COVID-19 pandemic in Southern Brazil, regarding the B.1.1.28, B.1.91 and B.1.1.33 lineages identified. The novel mutation (Y380Q) with C379W, modifies important RBD properties, which may interfere with the binding of neutralizing antibodies (CR3022, EY6A, H014, S304). HighlightsO_LICharacterization of novel mutation (Y380Q) in RBD of SARS-CoV-2 spike protein C_LIO_LIThe Y380Q and C379W modify important properties in the SARS-CoV-2 RBD region C_LIO_LIThe RBD mutations may interfere with the binding of neutralizing antibodies C_LIO_LIThe B.1.1.28, B.1.91 and B.1.1.33 lineages were circulating in early pandemic C_LI
- organism: human
- assay: whole-genome sequencing
- research focus: variant calling
- approach: statistical model
- Citations
- 5
- FWCI
- 0.61
- Field percentile
- top 34%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Neutralization of European, South African, and United States SARS-CoV-2 mutants by a human antibody and antibody domains
- Spike mutations that affect the function and antigenicity of recent KP.3.1.1-like SARS-CoV-2 variants
Bernadeta Dadonaite, Sheri Harari, … Jesse D. Bloom·Journal of VirologyPeer-reviewed·Oct 13, 2025
- SARS-CoV-2 variant with higher affinity to ACE2 shows reduced sera neutralization susceptibility
M. Vogel, X. Chang, … M. F. Bachmann·bioRxiv·Mar 4, 2021
- Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
M. Yuan, D. Huang, … I. A. Wilson·bioRxiv·Feb 16, 2021
- The impact of Spike mutations on SARS-CoV-2 neutralization
C. Rees-Spear, L. Muir, … L. E. McCoy·bioRxiv·Jan 15, 2021
- Relative Mutant N501Y SARS-CoV-2 Spike Protein RBD Inhibition of Anti-Spike Protein IgG and ACE-2 Binding to Spike Protein Species
M. E. Klegerman, J. D. Cirillo, D. D. McPherson·bioRxiv·Apr 26, 2021